Healthcare [ 13/13 ] | Biotechnology [ 106/161 ]
NYSE MKT | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.14 Decreased by -121.65% | - |
| Aug 14, 23 | -0.07 Decreased by -0.43% | - |
| May 12, 23 | -0.09 Decreased by -23.43% | - |
| Mar 31, 23 | -0.07 Decreased by -18.67% | - |
| Nov 10, 22 | -0.06 Decreased by -28.4% | - |
| Aug 12, 22 | -0.07 Increased by 0% | - |
| May 13, 22 | -0.07 Decreased by -40% | - |
| Mar 29, 22 | -0.06 Increased by 0% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 46 K Increased by +411.11% | -5.4 M Decreased by -62.63% | Decreased by -11.74 K% Increased by +68.18% |
| Jun 30, 23 | 9 K Decreased by -25% | -2.67 M Increased by +26.78% | Decreased by -29.66 K% Increased by +2.37% |
| Mar 31, 23 | 10 K Increased by +100% | -5.5 M Decreased by -63.76% | Decreased by -55.04 K% Increased by +18.12% |
| Dec 31, 22 | 8 K Decreased by -70.37% | -2.7 M Decreased by -25.3% | Decreased by -33.8 K% Decreased by -322.89% |
| Sep 30, 22 | 9 K Decreased by -62.5% | -3.32 M Decreased by -69.87% | Decreased by -36.9 K% Decreased by -352.99% |
| Jun 30, 22 | 12 K Decreased by -67.57% | -3.65 M Decreased by -47.33% | Decreased by -30.38 K% Decreased by -354.27% |
| Mar 31, 22 | 5 K Decreased by -91.07% | -3.36 M Decreased by -60.97% | Decreased by -67.22 K% Decreased by -1.7 K% |
| Dec 31, 21 | 27 K Decreased by -94.65% | -2.16 M Increased by +11.77% | Decreased by -7.99 K% Decreased by -1.55 K% |
As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.